Clinical Trials Logo

Anal Squamous Cell Carcinoma clinical trials

View clinical trials related to Anal Squamous Cell Carcinoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04596033 Terminated - Clinical trials for Non-small Cell Lung Cancer

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Start date: November 11, 2020
Phase: Phase 1
Study type: Interventional

TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, Genocea confirms which cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune cells that recognize these cancer proteins are multiplied many times (a process called PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in one or more intravenous (IV) infusions.

NCT ID: NCT02407561 Terminated - Clinical trials for Rectal Adenocarcinoma

Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

Start date: February 2015
Phase: N/A
Study type: Observational

Patients with locally advanced rectal and esophageal carcinomas typically undergo neoadjuvant chemoradiation therapy prior to surgical resection. While response rates to this treatment differ among these three cancers, generally 20-25% of patients exhibit minimal or no response to preoperative chemoradiation therapy while 20-30% exhibit a complete pathologic response, and the remainder receiving a partial response. This will be a multi-center study of patients with newly diagnosed rectal adenocarcinoma, or anal squamous cell carcinoma (SCC) who will undergo neoadjuvant chemoradiation prior to surgery. The tumor from these patients will be tested to determine whether response to neoadjuvant chemoradiation can be accurately predicted.